What the FDA labels say about taking them together
Celecoxib and pemetrexed
Celecoxib's FDA label of November 22, 2024 names pemetrexed in its drug interactions section; the pemetrexed labels PlainMeds reads (4) do not name celecoxib. The celecoxib label: “Concomitant use of CELEBREX and pemetrexed may increase the risk of pemetrexed-associated myelosuppression, renal, and GI toxicity.”
Check it at the source: the celecoxib FDA label on DailyMed (effective November 22, 2024, Viatris Specialty LLC); the pemetrexed FDA label on DailyMed (effective October 8, 2025, Avyxa Pharma, LLC).
What does the celecoxib label say about pemetrexed?
Celecoxib label, drug interactionsPemetrexed Clinical Impact: Concomitant use of CELEBREX and pemetrexed may increase the risk of pemetrexed-associated myelosuppression, renal, and GI toxicity (…). Intervention: During concomitant use of CELEBREX and pemetrexed, in patients with renal impairment whose creatinine clearance ranges from 45 to 79 mL/min, monitor for myelosuppression, renal and GI toxicity. …
Elyxyb - Celecoxib label (SCILEX PHARMACEUTICALS INC., November 26, 2024), drug interactionsClinical Impact; Concomitant use of celecoxib and pemetrexed may increase the risk of pemetrexed-associated myelosuppression, renal, and GI toxicity (see the pemetrexed prescribing information).
Source: FDA drug label (Vyscoxa, NDA211759), Carwin Pharmaceutical Associates, LLC, effective July 31, 2025 (SPL set 5094d47e-f791-4190-9397-b7500143a74d), via openFDA
Source: FDA drug label (Elyxyb - Celecoxib, NDA212157), SCILEX PHARMACEUTICALS INC., effective November 26, 2024 (SPL set c8a5de07-9f27-4a54-a885-8089f0307bd7), via openFDA
Source: FDA drug label (CELEBREX), NDA020998 (Upjohn), as published by Viatris Specialty LLC, effective November 22, 2024 (SPL set 2d6675e4-5859-4be2-8037-a20ce9f707aa), via openFDA; the full label on DailyMed
What does the pemetrexed label say about celecoxib?
Pemetrexed's label (effective October 8, 2025) and its 3 other brand-application labels do not name celecoxib in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (AXTLE), Avyxa Pharma, LLC, effective October 8, 2025 (SPL set 9582c46c-d8b0-44b7-a2ee-9c86f5e9b7b1), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Celecoxib | Pemetrexed | |
|---|---|---|
| Labeled for | Osteoarthritis, Rheumatoid arthritis, Pain, Migraine | Lung cancer |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $0.0762 per capsule 200 mg capsule | n/a |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once